Search results
Senator slams drugmaker for seeming to skirt pledge to cap inhaler cost
The Hill via AOL· 1 day agoDrug manufacturing giant GSK is subverting its pledge to lower the price of its brand-name inhaler...
Sen. Hassan slams GlaxoSmithKline over cost of asthma inhalers
New Hampshire Union Leader· 2 days agoPharmaceutical giant GlaxoSmithKline is sidestepping its pledge to lower asthma inhaler prices, a...
The FTC Strikes Again – Challenging the Listing of 300+ Patents in FDA’s Orange Book | JD Supra
JD Supra· 23 hours agoThe warning letters stated that the identified patents were not necessarily an exhaustive list and stressed the companies’ burden to ensure patents in the Orange Book are ...
Small Business - Cordele Dispatch | Cordele Dispatch
Cordele Dispatch· 2 days agoPDUFA Target Action Date of June 26, 2024 Eight posters including two oral presentations support potential of ensifentrine,an investigational, first-in-class, selective, dual inhibitor of PDE3 and PDE4 LONDON and RALEIGH, N.C., May 02, 2024
Lawsuit accuses Boehringer Ingelheim of false patent listings
Hartford Business Journal· 2 days agoThe named defendants in the lawsuit are Boehringer Ingelheim Pharmaceuticals Inc., based in...
FTC targets ‘junk patents’ on Ozempic, other top drugs
BioPharma Dive via Yahoo Finance· 3 days agoThe move broadens the antitrust regulator’s campaign against allegedly “improper or inaccurate”...
Afrezza: Mild to serious side effects and how to manage them
Medical News Today· 18 hours agoAfrezza (insulin human) is a brand-name inhaled insulin prescribed to manage blood sugars in adults...
Amazon, AMD, and Super Micro Sing the Same Sad Song, and 5 Other Things to Know Before Markets Open.
Barrons.com· 3 days agoTesla takes action amid slowing growth at fast-charging stations, Walmart unveils premium...
FTC challenges 'junk' patents held by 10 drugmakers, including for Novo Nordisk's Ozempic
CNBC· 4 days agoThe Federal Trade Commission on Tuesday said it is challenging hundreds of alleged "junk" patents...
Novo’s Blockbuster Ozempic Among FTC’s Latest Patent Targets
Bloomberg Law· 4 days agoOzempic and Victoza are among 20 branded drugs the Federal Trade Commission is targeting as it challenges more than 300 “junk patent listings” in the FDA’s registry of approved drugs in an effort ...